Publications

Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti A. at al., New England Journal of Medicine,
vol 360: 447 -458, 2009

Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers
Andersen R.S. at al., Natural Protocols,
vol 7: 891 - 902, 2012

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Bendle G.M. at al., Nature Medicine,
vol 16: 565 - 571, 2010

Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells
Boitano A.E. et al., Science,
vol 329: 1345 - 1348, 2010

Safety of retroviral gene marking with a truncated NGF receptor
Bonini C. at al., Nature Medicine,
vol 9: 367 - 369, 2003

HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini C. at al., Science,
vol 276: 1719 - 1724, 1997

Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome
Boztug K. at al., New England Journal of Medicine,
vol 363: 1918 - 1927, 2010

A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown B.D. at al., Blood,
vol 110: 4144 - 4152, 2007

Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer
Brown B.D. at al., Nature Medicine,
vol 12: 585 - 591, 2006

Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease
Stein et al., Nature Medicine,
vol 16, number 2:198-205, 2010

An unbiased genome-wide analysis of zinc-finger nuclease specificity
Gabriel et al., Nat Biotech,
vol 29, number 9: 816-824, 2011

Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier et al., Science
number 326: 818-823, 2009

The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, Molecular Cell
number 40: 179-204, 2010

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study
Ciceri et al., Lancet Oncol.,
Vol 10:489-500, 2009

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Cieri et al., BLOOD,
vol 121, number 4: 573-584, 2013

Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution
Delaney et al., Nat. Med.
vol 16, number 2: 232-237, 2010

Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice
Follenzi et al., Blood, 
vol 103, number 10: 3700-3709, 2004

An unbiased genome-wide analysis of zinc-finger nuclease specificity
Gabriel et al., Nat Biotechnol,
vol 29 number 9: 816-823, 2011

Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction
Gaspar et al., Sci Transl Med,
vol 3: 1-9, 2011 a

Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency
Gaspar et al., Sci Transl Med,
vol 3: 1-9, 2011 b

A human memory T cell subset with stem cell–like properties
Gattinoni et al., Nat. Med. ,
vol 17, number 10: 1290-1297, 2011

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina et al., J Clin Invest.,
vol 118, number 9 3132-3142, 2008

Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency
Hacein-Bey-Abina, New Engl J Med
vol 363, number 4, 355-364, 2010

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers
Hadrup et al., Nat. Methods,
vol 6, number 7 520-526, 2009

Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells
Himburg et al., Nat Med.,
vol 16, number 4, 475-482, 2010

Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation
Hoggatt et al., Blood,
vol 113, number 22, 5444-5455, 2009

Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients
Howe et al., J Clin. Invest.,
vol 118, number 9, 3143-3150, 2008

Immunotherapy through TCR gene transfer
Kessels et al., Nat. Immunol.,
vol 2, number 10,957-961, 2001

Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery
Lombardo et al., Nat. Biotechnol.,
vol 25, number 11,1298-1306, 2007

Site-specific integration and tailoring of cassette design for sustainable gene transfer
Lombardo et al., Nat. Methods,
vol 8, number 10, 861-869, 2011

Thymus-autonomous T cell development in the absence of progenitor import
Martins, J. Exp. Med.,
vol 209, number 8,1409-1417, 2012

Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Morgan et al., Science,
vol 314, number 6, 126-129, 2006

TALE nucleases: tailored genome engineering made easy
Mussolino, Curr. Opin. Biotechnol.,
number 23:644–650, 2012

Hematopoietic Stem Cell Development Is Dependent on Blood Flow
North et al., Cell,
number 137, 736–748, 2009

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Provasi, Nat Med 
vol 18, number 5, 807-815, 2012

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically EngineeredLymphocytes Reactive With NY-ESO-1
Robbins, J Clin Oncol.,
vol 29, number 7 , 917-924, 2011

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Rosenberg et al., Clin. Cancer Res.,
number 17: 4550-4557, 2011.

Mapping the life histories of T cells
Schumacher, Nat. Rev. Immunol.,
vol 10, 621-631, 2010

Autonomous zinc-finger nuclease pairs for targeted chromosomal deletion
Sollu, Nucleic Acid Res.,
vol.38, number 22, 8269–8276, 2010

Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease
Stein, Nature,
vol.16, numer 2, febbraio 2010 Nature Medicine

Design and use of conditional MHC class I ligands
Toebes et al., Nat. Medicine,
vol. 38, number 22, 8269–8276, 2006

Genome editing with engineered zinc finger nucleases
Urnov et al., Nat. Rev. Genet.,
vol. 11, 2010

Recruitment of Antigen-Specific CD8+ T Cells in Response to Infection Is Markedly Efficient
van Heijst et al., Science,
vol 325, number 4, 1265-1269, 2009

Therapeutic gene causing lymphoma
Woods, Nature,
vol 440, number 27, 1123, 2006

Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. Nat Med. 2017 Jan 6;23(1):18-27. doi: 10.1038/nm.4241.

Cartier-Lacave N, Ali R, Ylä-Herttuala S, Kato K, Baetschi B, Lovell-Badge R, Naldini L, Thrasher A. Debate on Germline Gene Editing. Hum Gene Ther Methods. 2016 Aug;27(4):135-42. doi: 10.1089/hgtb.2016.28999.deb.

Cossu G, Previtali SC, Napolitano S, Cicalese MP, Tedesco FS, Nicastro F, Noviello M, Roostalu U, Natali Sora MG, Scarlato M, De Pellegrin M, Godi C, Giuliani S, Ciotti F, Tonlorenzi R, Lorenzetti I, Rivellini C, Benedetti S, Gatti R, Marktel S, Mazzi B, Tettamanti A, Ragazzi M, Imro MA, Marano G, Ambrosi A, Fiori R, Sormani MP, Bonini C, Venturini M, Politi LS, Torrente Y, Ciceri F. Intra- arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne

muscular dystrophy. EMBO Mol Med. 2016 Dec 1;8(12):1470-1471. doi: 10.15252/emmm.201607129.

Norelli M, Casucci M, Bonini C, Bondanza A. Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. Biochim Biophys Acta. 2016 Jan;1865(1):90-100.

Naldini L. Gene therapy returns to centre stage. Nature. 2015 Oct 15;526(7573):351-60. doi: 10.1038/nature15818.

Bonini C, Mondino A. Adoptive T-cell therapy for cancer: The era of engineered T cells. Eur J Immunol. 2015 Sep;45(9):2457-69. doi: 10.1002/eji.201545552.

Bosley KS, Botchan M, Bredenoord AL, Carroll D, Charo RA, Charpentier E, Cohen R, Corn J, Doudna J, Feng G, Greely HT, Isasi R, Ji W, Kim JS, Knoppers B, Lanphier E, Li J, Lovell-Badge R, Martin GS, Moreno J, Naldini L, Pera M, Perry AC, Venter JC, Zhang F, Zhou Q. CRISPR germline engineering--the community speaks. Nat Biotechnol. 2015 May;33(5):478-86.

Oliveira G, Ruggiero E, Stanghellini MT, Cieri N, D'Agostino M, Fronza R, Lulay C, Dionisio F, Mastaglio S, Greco R, Peccatori J, Aiuti A, Ambrosi A, Biasco L, Bondanza A, Lambiase A, Traversari C, Vago L, von Kalle C, Schmidt M, Bordignon C, Ciceri F, Bonini C. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Sci Transl Med. 2015 Dec 9;7(317):317ra198.

Greco R, Oliveira G, Stanghellini MT, Vago L, Bondanza A, Peccatori J, Cieri N, Marktel S, Mastaglio S, Bordignon C, Bonini C, Ciceri F. Improving the safety of cell therapy with the TK- suicide gene.
Front Pharmacol. 2015 May 5;6:95. doi: 10.3389/fphar.2015.00095.

Cieri N, Oliveira G, Greco R, Forcato M, Taccioli C, Cianciotti B, Valtolina V, Noviello M, Vago L, Bondanza A, Lunghi F, Marktel S, Bellio L, Bordignon C, Bicciato S, Peccatori J, Ciceri F, Bonini C.

Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood. 2015 Apr 30;125(18):2865-74. doi: 10.1182/blood-2014-11-608539.

Biasco L, Scala S, Basso Ricci L, Dionisio F, Baricordi C, Calabria A, Giannelli S, Cieri N, Barzaghi F, Pajno R, Al-Mousa H, Scarselli A, Cancrini C, Bordignon C, Roncarolo MG, Montini E, Bonini C, Aiuti A. In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Sci Transl Med. 2015 Feb 4;7(273):273ra13. doi: 10.1126/scitranslmed.3010314.

Lombardo A & Naldini L. Genome editing: a tool for research and therapy: targeted genome editing hits the clinic. Nature Medicine. 2014 Oct;20(10):1101-3.

Genovese P, Schiroli G, Escobar G, Di Tomaso T, Firrito C, Calabria A, Moi D, Mazzieri R, Bonini C, Holmes MC, Gregory PD, van der Burg M, Gentner B, Montini E, Lombardo A, Naldini L. Targeted genome editing in human repopulating haematopoietic stem cells. Nature. 2014 Jun 12;510(7504):235-40.

Highlighted in Nature: News & Views: Fischer A. Gene therapy: Repair and replace. Nature. 2014 Jun 12;510(7504):226-7. doi: 10.1038/nature13344.

Noviello M, Saverio Tedesco F, Bondanza A, Tonlorenzi R, Carbone MR, Gerli M; Marktel S, Napolitano S, Cicalese MP Ciceri F, Peretti G, Cossu G, Bonini C. Inflammation converts mesoangioblasts into targets of alloreactivity: implications for allogeneic cell therapy of DMD. Mol Ther. 2014 Jul;22(7):1342-52.

Cieri C, Mastaglio S, Oliveira G, Casucci M, Bondanza A, Bonini C. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunol Rev. 2014 Jan;257(1):165-80.

C. Linnemann , M.M. van Buuren, L. Bies, E.M. Verdegaal, R. Schotte, J.J. Calis, S. Behjati, A. Velds, H. Hilkmann, D. el Atmioui, M. Visser, M.R. Stratton, J.B. Haanen, H. Spits, S.H. van der Burg and T.N. Schumacher. High throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T-cells in human melanoma. Nat Med. 2015.

S. Becattini, D. Latorre, F. Mele, M. Foglierini, C. De Gregorio, A. Cassotta, B. Fernandez, S. Kelderman, T.N. Schumacher, D. Corti, A. Lanzavecchia, F. Sallusto. Functional Heterogeneity Of Human Memory T Cell Clones Primed By Pathogens Or Vaccines. Science, 2015.

Knipping F, Petri K, Osborn MJ, Tolar J, Glimm H, von Kalle C, Schmidt M, Gabriel R. Genome- wide specificity of highly efficient TALEN and CRISPR/Cas9 for T cell receptor modification. Submitted to Molecular Therapy Nucleic Acids

Ruggiero E, Nicolay JP, Fronza R, Arens A, Paruzynski A, Nowrouzi A, Ürenden G, Lulay C, Schneider S, Goerdt S, Glimm H, Krammer PH, Schmidt M, von Kalle C. High-resolution analysis of the human T-cell receptor repertoire. Nat Commun. 2015 Sep 1;6:8081.

Gabriel R, von Kalle C, Schmidt M. Mapping the precision of genome editing. Nat Biotechnol. 2015 Feb;33(2):150-2.

Gabriel R, Kutschera I, Bartholomae CC, von Kalle C, Schmidt M. Linear amplification mediated PCR--localization of genetic elements and characterization of unknown flanking DNA. J Vis Exp. 2014 Jun 25;(88):e51543

Hacein-Bey-Abina et al, A modified γ-retrovirus vector for X-linked severe combined immunodeficiency, NEJM 2014 Oct 9;371(15):1407-17

ESGCT / ISSCR / ABCD COLLABORATIVE CONGRESS - October 2016, Florence, Italy 


ASGCT 18th Annual Meeting (May 2015, New Orleans, USA 


Genome Editing for Gene and Cell Therapy Symposium, Hannover, Germany, 11/2016 


Annual Meeting of ESGCT and ISSCR, Florence, Italy, 10/2016 


19th Annual Meeting of ASGCT, Washington, DC, USA, 5/2016 


Annual Meeting of ESGCT and FSGT, Helsinki, Finland, 9/2015 


18th Annual Meeting of ASGCT, New Orleans, USA, 5/2015 


Annual Meeting of ESGCT and NVGCT, The Hague, Netherlands, 10/2014 


17th Annual Meeting of ASGCT, Washington, DC, USA, 5/2014 


XX Annual Meeting of DG-GT, Ulm, Germany, 3/2014 


Annual Meeting of ESGCT and SETGyC, Madrid, Spain, 10/2013 
ASGCT 17th Annual Meeting (May 2014, Washington D.C.): 
• Disrupting the Endogenous TCR expression by TALEN and RNA-Guided Nucleases • Discovering the Human T Cell Receptor Repertoire BY Deep Sequencing 


 

ASGCT 19th Annual Meeting Washington DC, 4-7 May 2016, Giuliani E. et al. “Purification of Large Scale mRNA Encoding ZFN Nucleases by dHPLC Technology

ESGCT/ISSCR/ABCD Collaborative Congress, Florence, 18-21 October 2016, Giuliani E. et al., “

Production, purification and nucleofection of large scale mRNA encoding ZFN nucleases into human primary T cells and CD34+ cells

AAAS 2016 Annual Meeting, Washington, USA, 11-15/02/2016 “TCR Gene Editing to Treat Hematological Malignancies”, Bonini C.

Young Investigator Award Lecture at the ESGCT / ISSCR / ABCD COLLABORATIVE CONGRESS - October 2016, Florence, Italy
• T owards clinical translation of gene editing technologies for empowering adoptive

immunotherapy or correcting inherited mutations

Presentations at the ESGCT / ISSCR / ABCD COLLABORATIVE CONGRESS - Oct 2016, Florence, Italy
• Advanced genetic engineering of hematopoiesis to treat human diseases
• TCR gene edited memory stem T cells for cancer immunotherapy

• Multiple inhibitory receptors are expressed on central memory and memory stem T cells infiltrating the bone marrow of AML patients relapsing after allo-HSCT

Invited Lecture: Future Medicine / Innovation in Health Sciences – Nov. 2016, Berlin, Germany.

BIOGEN IDEC, Boston, USA, 13/10/16
Seminar “Advancing applications of hematopoietic stem cells and liver-directed gene therapy by lentiviral gene transfer and targeted gene editing “

Georgetown University Italian Research Institute, Washington, USA, 14/10/16
Lecture “Turning Foes into Friends: Exploiting HIV for the Gene Therapy of Inherited Diseases and Cancer”

ESGCT-ISSCR Joint Meeting Florence 2016 October 18/21 :
Lecture: Advanced genetic engineering of hematopoieisis to treat human diseases.

The 58th Annual Meeting of the Japanese Society for Inherited Metabolic Diseases, 27-29 October 2016, Tokyo, Japan
Special Lecture “Genetic Engineering of Human Hematopoiesis for the Treatment of Inherited Diseases and Cancer”

Invited Lecture: 5th International Conference of the Cyprus Society of Human Genetics – October 2016, Cyprus.

Highlights From EHA – Firenze 17/09/16
Lettura Speciale “Terapia genica con cellule staminali ematopoietiche: dal gene transfer all’editing genico mirato”

Invited Lecture: 1st Annual Symposium on Cell and Gene Therapy - Christian Medical College Campus, August 2016, Vellore, India.

ASH Workshop on Genome Editing (Washington DC), July 14-15, 2016 “Gene Editing of HSC for the therapy of inherited diseases”

Invited Lecture: Genome Editing Science Club - Giannina Gaslini Institute, June 2016, Genoa, Italy.

Festival Della Scienza Medica. Le Eta' Della Vita - 19-22 Maggio 2016
Tavola Rotonda su “il futuro delle biotecnologie: opportunità di Innovazione e crescita sostenibile”

Retreat TIGEM-DTI , 26-28 Maggio 2016, Roma

FASEB Science Research Conference Genome Engineering – Cutting-Edge Research and Applications, Lisbon, Portugal, June 05-10, 2016
“HSC-mediated gene therapy of inherited diseases: from gene replacement to gene editing”

European Hematology Conference: Copenhagen, Denmark, June 09-12 2016 Targeted genome editing in hematopoietic stem cells

SIBBM 2016, June 17 2015, Naples, Italy
“Genetic Engineering of Hematopoiesis to treat Inherited Diseases and Cancer”

Invited Lecture: Annual Meeting of the French society of cellular and gene therapy (SFTCG) - March 2016, Marseilles, France.

1st Symposium of the Vienna Center for Rare and Undiagnosed Diseases, which will take place 19-20 February 2016 in Vienna
“Genetic Engineering of Hematopoiesis to treat inherited diseases and cancer”

Federation of European Academies of Medicine “European workshop on Human Genome Editing: Opportunities and Challenges for Europe”, 28 April 2016

Chair in the Session 3: Clinical research and applications in human somatic cells–current state, opportunities, and regulation

ASGCT 19th Annual Meeting

“HSC-based gene therapy of inherited diseases and cancer”

XLVIII Jiménez Díaz Memorial Lecture. Madrid, 17 May 2016
“Turning Foes into Friends: Exploiting HIV for the Gene Therapy of Inherited Diseases and Cancer”

ENCALS Meeting (network of ALS centres in Europe): Milan, Italy , May 19th, 2016
Opening lecture: “La T erapia Genica con cellule Staminali Ematopoietiche: dal bancone di laboratorio al letto del paziente”

Invited Lecture: 18th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) - May 2015, New Orleans, USA.

Presentations at the ASGCT 19th Annual Meeting (May 2016, Washington D.C., USA):

•   Correction of SCID-X1 by Targeted Genome Editing of Hematopoietic Stem/Progenitor Cells 
(HSPC) in the Mouse Model 


•   Towards Clinical Translation of Hematopoietic Stem Cell Gene Editing for the Correction of 
SCID-X1 Mutations

Hearing at the Council of Europe_Secretariat of the Committee on Social Affairs, Health and Sustainable Development of the Parliamentary Assembly of the Council of Europe: Thursday 1st of October 2015, the European Palace in Strasbourg. 
“Manufacturing the new human species”. 


2015 Biomedical Symposium on Stem Cell Biology, St. Jude Children's Research Hospital October 23, 2015
“Genetic engineering of hematopoiesis to treat inherited disease and cancer”

 
Workshop organized by the ESPGHAN (European Society for Paediatric Gastroenterology Hepatology and Nutrition) and Genethon entitled: Targeting liver disease at DNA level-Novel Diagnostic Tools and Gene Transfer Technologies in Paediatric Hepatology. Venice, Italy the 29-30 October 2015. 
“Lentiviral gene transfer to the liver” 


EMBO/EMBL Science & Society Conference, Heidelberg
“Blood Stem Cell Gene Therapy to fight inherited diseases and cancer”


The EBMT Cellular Therapy and Immunobiology Symposium From Transplantation to Gene Therapy: cellular therapy in evolution, San Raffaele Scientific Institute, 11-13 November 2015 “Lentiviral Vectors and Nucleases”

ASH 2015. Presidential Symposium:
“Gene Replacement and Targeted Genome Editing in Hematopoietic Stem Cells for the Treatment of Human Diseases”

Presentations at the ESGCT 22th Annual Meeting (October 2015, Helsinki, Finland): 


•   Targeted Genome Editing in Human Long-Term Repopulating Hematopoietic Stem Cells for the 
Correction of SCID-X1 


•   Targeted Genome Editing in Mouse Hematopoietic Stem/Progenitor Cells (HSPC) to model Gene 
Correction of SCID-X1



•    Presentations at the ASGCT 18th Annual Meeting (May 2015, New Orleans, USA): 


• Targeted Genome Editing in Mouse Hematopoietic Stem/Progenitor Cells (HSPC) to model Gene Correction of SCID-X1

Keynote Lecture at the EMBO Conference on “Cell therapy today: achievements, hopes and hypes”. Manchester 09th and 10th September 2015
"Genetic engineering of hematopoietic stem cells for the treatment of inherited diseases and cancer"

The Annual Meeting of the European Society of Gene and Cell Therapy (ESGCT), which this year is organized in collaboration with the Finnish Society of Gene Therapy (FSGT) to take place September 17-20, 2015 in Helsinki, Finland.
“Gene transfer by lentiviral vectors and gene editing from bench to bedside”

Keynote Lecture at the 13th European Congress of Toxicological Pathology in collaboration with the British Society of Toxicological Pathology (UK) , University of Surrey in Guildford, United Kingdom, September 22nd to 25th , 2015
Gene Therapy Overview.

“Doctor Honoris Causa - Distinguished Lecture” at the Faculty of Medicine and Pharmacy, The Vrije Universiteit Brussel, 28 May 2015
"Genetic engineering of human hematopoietic stem cells for the treatment of inherited diseases and cancer"

Lettura magistrale presso la Scuola Superiore Sant’Anna nell'ambito del ciclo seminariale dal titolo "Orizzonti in Biologia e Medicina" Venerdì 05 Giugno 2015
"La terapia genica con cellule staminali ematopoietiche: dal laboratorio al letto del paziente".

Lecture at the Venetian Institute of Molecular Medicine - June 9th, 2015
Genetic Engineering of Human Hematopoiesis for Treating Inherited Diseases and Cancer”

“Giornata dei Giovani Ricercatori”, Policlinico San Donato, 16 giugno 2015 - La terapia genica con cellule staminali.

Annual Meeting for the International Society for Stem Cell Research, Stockholm, June 24-27 2015

The 3rd International Michelangelo Conference on “Promises and challenges of developing new drugs in oncology”, Milan, Italy 2nd and 3rd July 2015 at the Museo della Scienza e della Tecnologia,
Engineered cells for cancer therapy.

8th Stem Cell Clonality and Genome Stability Retreat, New Orleans, USA Lettura Accademia Medica Roma, 22 Gennaio 2015

“ La Terapia Genica con Cellule Staminali Ematopoietiche: dal laboratorio al letto del paziente ”

Gordon Conference: Lysosomal Diseases, 03/15/2015 - 03/20/2015, Location: Hotel Galvez in Galveston TX United States

TEDxRoma, evento della grande community TED, 21 marzo 2015 al Teatro Olimpico, Roma “HIV, un cavallo di Troia per la terapia genica”

Symposium on "Novel therapies for monogenic diseases" at the Collège de France in Paris on April 16th -17th, 2015.

Key note lecture - Meeting of the Austrian Society of Hematology and Medical Oncology - 23rd

April 2015
"Targeted Genome Editing - Possibilities of Clinical Application"

International Sympsium on Hematopoietic Stem Cells (Tubingen); April 22nd to April 25th 2015; “Targeted genome engineering of HSC for treating genetic diseases and cancer”

First CRG course in "Somatic Cell Reprogramming"; 7-12th November 2014, Barcelona. “Genetic Engineering of Hematopoietic Stem Cells for treating Human Disease”.

Premio Agostinelli (Accademia delle Scienze Torino); 10 Novembre 2014, Torino.
IV Edition of the International Conference "Bioeconomy Rome 2014", 13 November 2014. ETH Zurich/D-BSSE departmental seminar, 25 November 2014, Zurich, CH.

Presentations at the ASGCT 17th Annual Meeting (May 2014, Washington D.C.):

•       Single Edited T Cells Redirected Towards NY-ESO-1 Ensure Tumor Rejection Without Inducing 
Xenogeneic GvHD 


•       Site-Specific Genome Editing in Human Long-Term Repopulating Hematopoietic Stem Cells for 
Correction of SCID-X1 
Outstanding Achievement Award Lecture at the ASGCT 17th Annual Meeting (May 2014, Washington D.C.): 


• Lentiviral Vectors from Bench to Bedside: A Lifetime Journey

Invited Lecture: “Use of genetically modified T lymphocytes in HSCT.” 7th International Symposium Haploidentical Stem Cell Transplantation, Weizmann Institute of Science, Israel, Feb 9-10, 2014.

Invited Lecture: “Memory stem T cells.” GvH/GvL Symposium, Regensburg, Germany, March 26- 28, 2014.

Invited Lecture: “Use of genetically modified Lymphocytes in allogeneic stem cell transplantation” EBMT Annual Meeting Milano March 31- April 2, 2014.

Invited Lecture: “Editing T cell Specificity Towards Leukemia by Zinc Finger Nucleases and Lentiviral Gene Transfer.” Educational Program. ASGCT Annual Meeting, Washington DC. May 20-24th 2014.

Presentations at the ASGCT 16th Annual Meeting (May 2013, Salt Lake City):
• TCR Gene Editing to Treat Acute Leukemia and Multiple Myeloma
• Efficient Site-Specific Integration and In Situ Gene Correction of Human Long-Term

Repopulating Hematopoietic Stem Cells

Keynote Lecture at FASEB Meeting: Genome Engineering: Cutting-Edge Research and Application (June 2013; Nassau, Bahamas):
• Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells

Invited Lecture: Immunotherapy of Leukemia with TCR transduced T cells. EBMT Immunobiology Working part Educational Event. Perugia, IT September 2013.

Invited Lecture: CIK or central memory cells for adoptive immunotherapy? The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany, October 10-13, 2013.

Invited Lecture: Bases of Gene Therapy in Leukemias. ESGCT Annual Meeting. Madrid October 25-28 2013.

Invited Lecture: TCR gene editing for the treatment of hematological malignancies. ESGCT Annual Meeting. Madrid October 25-28 2013.

Invited Lecture: TCR editing, suicide gene e CARs come principali strategie di terapia genica in campo oncologico. Immunoterapia Antitumorale e Terapia Genica: Regole e Sperimentazione, Milano, IT 4 Novembre 2013.

Invited Lecture: “Ex Vivo T-Cell depletion”. Scientific Symposium of the Acute Leukemia Working Party (ALWP) European Group for Blood and Marrow Transplantation (EBMT). Marseille, Nov 22-23, 2013.

 

Invited lecture: CRUK Clinical Research Centre Southampton, February 12, 2014, Southampton, UK. What T cells see on human cancer?

Invited lecture: CIML seminar series, March 12, 2014, Marseille, FR. Neo-antigen specific T cell reactivity in cancer immunotherapy.

Invited lecture: San Raffaele Institute, March 18, 2014, Milan, IT. What T cells see on human cancer?

Invited lecture: MSKCC Immunology series March 23, 2014, New York, USA. What T cells see on human cancer?

Invited lecture: MD Anderson, March 24, 2014, Houston, USA. What T cells see on human cancer Invited lecture: Max Planck Institute Freiburg seminar series, April 3, 2014, Freiburg, DE.

Dissection of antigen specific T cell responses in mice and men

Acceptance speech: San Salvatore Award, May 17, 2014, Lugano, CH. What T cells see on human cancer?

Invited lectures: Weizmann Institute Immunology series, May 19-20, 2014, Rehovot, Israel. What T cells see on human cancer?

Invited lecture: Oslo Cancer Symposium, June 10-11, 2014, Oslo, Norway. Neo-antigen specific T cell reactivity in cancer immunotherapy.

Invited lecture: Harvard Medical School Immunology series, Sept 10, 2014, Boston USA. What T cells see on human cancer?

Invited lecture: MGH, Sept 11, 2014, Cambridge, USA. What T cells see on human cancer?
Invited lecture: DC2014 Symposium, Sept 15-17, 2014, Tours, Fr. What T cells see on human cancer?

Keynote lecture: ISGCT symposium, Sept 25-26, 2014, Amsterdam, The Netherlands. What T cells see on human cancer?

Invited Lecture: ESGCT and ISSCR Congress (17 - 22 October 2016, Florence)

Invited Lecture: ASGCT 18th Annual Meeting (13 – 16 May, New Orleans)

Invited Lecture: ESGCT and FSGT Congress (17 - 20 September 2015, Helsinki)

Invited Lecture: Genome Editing Congress (12 - 13 November 2015; London) - Genome-wide Analyses Of Gene Editing – On-and Off-target Modifications

Invited Lecture: 5th International Conference on Retroviral Integration (26 October 2014, Asilomar)
- Integration of Retroviral Vectors in Gene Therapy - Understanding and Avoiding Severe Side Effects

Invited Lecture: NIH Genome Editing workshop (10 June 2014, Washington D.C.): - Unbiased Capture Approaches to Identify Double Strand DNA Breaks

Invited Lecture: ASGCT 17th Annual Meeting (21-24 May 2014, Washington D.C.) - Integrating Vectors, Avoiding Oncogenesis

Oral Presentation: ASGCT 17th Annual Meeting (21-24 May 2014, Washington D.C.)

Oral Presentation: XXI Annual Meeting of DG-GT, Vienna, Austria, 2/2015

Oral Presentation: XXII Annual Meeting of DG-GT, Heidelberg, Germany, 9/2016

Oral Presentation at the ASGCT 17th Annual Meeting (21-24 May, Washington D.C.) - Integrating Vectors, Avoiding Oncogenesis

Oral Presentation at NIH Genome Editing workshop (10 June, Washington D.C.): - Unbiased Capture Approaches to Identify Double Strand DNA Breaks

ISCT, Paris, 23-26 April 2014.
“Gene correction of immune and metabolic defects”

ASGCT, Washington, 21st-24th May 2014
“Refining clinical trials for inherited immunodeficiencies”

Frontiers in Immunology - from molecules to disease, Stockholm 12-14 June 2014 “Maturing Gene Therapy for Primary Immunodeficiency”

PIDI course, Hong Kong, 20-21st June 2014
Roland Levinsky Memorial Lecture: “The path to effective gene therapies in inherited immunodeficiency”

ESGCT, The Hague 23rd-26th October 2014 “Progress in gene therapy for PIDs”

Third International Conference on Primary Immunodeficiency Diseases, Chennai, India, 21-23 February 2015
“Update on gene therapies and other stem cell modalities”

Modern Concepts in DNA – EMBO, Evry, 30th March-3rd April 2015 1. “LV in gene therapy of hematopoietic stem cells diseases”
2. “Update on current and future clinical trials for gene therapy”

Rare Diseases Conference, Oxford, 6-7th April 2015 "Maturing gene therapy for immunodeficiencies”

NIHR Rare Diseases TRC for Immune and Blood Rare Diseases

“Inherited immune disorders – An introduction”

BSGCT, Glasgow, 9-11th June 2015
“Evolving Gene Therapy for Primary Immunodeficiency”

IIC PID Course, Oxford 29th June – 1st July 2015 “Gene Therapy for Immunodeficiency – Job Done”

GENYO, Granada 7-9th July 2015
“Evolving safety and efficacy of gene therapy for immunodeficiencies”

2nd Biotest Immunology Forum, Royal College of Physicians, London, 30th September 2015 “Gene Therapy for PID”

Eurofancolen/Advances of Gene Therapy in monogenic diseases affecting the hematopoietic system, 8th-9th February 2016
“Evolving gene therapy inprimary immunodeficiencies”

Centre for Immunodeficiency Winter School, Windsor, 7th -9th March 2016 “Gene therapy for PID: update”

ESGCT, DG-GT and DZIF Spring School, 20th-22nd April 2016 “Developing successful gene therapies in immunological disorders”

Regulatory Science Symposium, NIBSC 40th Annivesary, London, 18th May 2016 “Gene therapy in severe immunodeficiency”

Annual Immunology Symposium with Pears Lecture, London, 21 June 2016 “Updates on clinical gene therapy for immunological disease”

XXII Annual Meeting of the German Society of Gene Therapy (DG-GT), Heidelberg, 14-16 September 2016
“Evolving Gene Therapy for Primary Immunodeficiency

Hematopoiesis: From basic biology to clinical medicine, Lund, 22-23 September 2016 “Evolving gene therapy for primary immunodeficiency”

World Life Science Conference, Beijing, 31 October– 4 November 2016 “Evolving gene therapy for human primary immunodeficiency”